October 3, 2016 / 1:02 PM / 10 months ago

BRIEF-Tracon pharmaceuticals announces successful meetings with FDA, EMA for TRC105 in Angiosarcoma

1 Min Read

Oct 3 (Reuters) - Tracon Pharmaceuticals Inc :

* Reached agreement with both regulatory agencies regarding key elements of phase 3 program for trc105 in angiosarcoma

* Tracon pharmaceuticals announces successful meetings with fda and ema for trc105 (carotuximab) in angiosarcoma

* Expects to initiate enrollment in phase 3 study by year-end Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below